Dextropropoxyphene versus morphine
in opioid-naive cancer patients with pain
by
Mercadante S, Salvaggio L, Dardanoni G, Agnello A, Garofalo S
Department of Anesthesia and Intensive Care,
Buccheri La Ferla Fatebenefratelli Hospital,
Palermo,
Italy.
J Pain Symptom Manage 1998 Feb; 15(2):76-81

ABSTRACT

The role of opioids for moderate pain (so-called "weak" opioids) in the second step of the World Health Organization's analgesic ladder has been investigated in a prospective randomized study. Sixteen patients were administered dextropropoxyphene (DPP) in a dosage ranging from 120 mg to 240 mg daily (group 1), and 16 patients were administered the lowest doses (20 mg daily) of commercially available controlled-release morphine (group 2). Equianalgesic doses of oral morphine, pain relief, and symptoms during the first 10 days of therapy and during the last 4 weeks before death were assessed. Three of 16 patients maintained DPP until death, whereas three patients in group 2 were switched to DPP due to the occurrence of intolerable side effects. Intensity and frequency of nausea and vomiting, drowsiness, and dry mouth were higher in group 2 than in group 1 during the initial treatment. These results stress the role of "weak" opioids during the induction of opioid therapy in opioid-naive cancer patients.

Pain
Arousal
Morphine
Tramadol
Naloxone
Nociceptin
Sufentanil
Oxycodone
Carfentanil
Endomorphins
Novelty and pain
Dihydroetorphine
Fentanyl and ketamine
Opioids and anaesthesia
Opioids, mood and cognition
Propoxyphene (Darvon) : structure
Dextropopoxyphene for postoperative pain
Propoxyphene (dextropropoxyphene): review
Popoxyphene (Darvon) subjective and physiological effects

Refs
HOME
HedWeb
BLTC Research
Designer Drugs
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?